Lycopene prevents adriamycin-induced testicular toxicity in rats.
OBJECTIVE
To investigate a possible protective role of lycopene on adriamycin (ADR)-induced spermiotoxicity using quantitative, biochemical and histopathological approaches.


METHODS
Experimental study.


METHODS
Firat University Medical School, Experimental Research Centre, Elazig, Turkey.


METHODS
Twenty four Sprague Dawley rats (8-weeks old)


METHODS
Adriamycin (10 mg kg(-1)) was intraperitoneally injected and lycopene (4 mg kg(-1)) was administered by gavage in corn oil.


METHODS
Reproductive organ weights were evaluated along with epididymal sperm concentration, motility and morphology. Testicular histological findings, oxidative status and plasma testosterone levels were also determined.


RESULTS
Lycopene ameliorated ADR-induced reductions in both testes and epididymis weights. ADR decreased sperm motility, increased total abnormal sperm rates, but epididymal sperm concentration was not changed compared to control. A marked normalization was achieved in sperm motility and morphology in pretreatment with lycopene. Although testosterone level was decreased in ADR group compared to control, no changes were observed in pretreatment group. An increase in malondialdehyde and a decrease reduced glutathione concentrations were detected in alone ADR group compared to control. Pretreatment with lycopene restored significantly malondialdehyde and reduced glutathione concentrations. ADR caused severe degenerative changes in germinative cells, atrophy in the diameter size of seminiferous tubules and germinative cell thickness. However, ADR-induced histopathological alterations were effectively reverted by pretreatment with lycopene.


CONCLUSIONS
This study clearly indicates that ADR treatment markedly impaired testicular function and that pretreatment with lycopene might prevent this toxicity.
Ateşşahin
Ahmet
A
Department of Pharmacology and Toxicology, University of Firat, Elaziğ, Turkey. aatessahin@hotmail.com
Türk
Gaffari
G
Karahan
Izzet
I
Yilmaz
Seval
S
Ceribaşi
Ali Osman
AO
Bulmuş
Ozgür
O
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D000975:Antioxidants / Q000008:administration & dosage; D002338:Carotenoids / Q000008:administration & dosage*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects*; D004347:Drug Interactions; D000077276:Lycopene; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013094:Spermatozoa / Q000187:drug effects* / Q000473:pathology*; D013737:Testis / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology
D000970:Antineoplastic Agents; D000975:Antioxidants; D002338:Carotenoids; D004317:Doxorubicin; D000077276:Lycopene